Take Your Clinical Decision Making to the Next Level with UpToDate

Dear Dr. Renukaprasad A R, Did you know that 95% of medical professionals find UpToDate® integral to their clinical practice? Every patient case is unique. As medicine becomes more complex and evidence evolves at a rapid pace, having a reliable clinical decision support resource can help you make the correct choices and improve patient outcomes. You can make choices about patient care with confidence, thanks to the point-of-care clinical decision support offered by UpToDate®. As a verified Docplexus user, you will receive special pricing on personal subscriptions to UpToDate®. Professional verified users: SAVE 15%  Resident verified users: SAVE 20% *Offer on annual and longer subscriptions only. Prices for Docplexus users are reflected on the UpToDate® storefront when you sign in to the Docplexus App with your user login credentials. Applicable taxes may apply. Proof of status is required for all resident orders. Visit the Storefront & Grab the Offer Click here to explore the infographics! Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Managing DED with PEG-PG/HP-Guar Artificial Tear

Dear Dr. Renukaprasad A R, Dry eye disease (DED) is one of the most common causes of ocular morbidity in patients presenting to an ophthalmology outpatient department. Did you know that artificial tear with hydroxypropyl guar (HP-guar) containing polyethylene glycol-propylene glycol (PEG/PG) is more effective than CMC? Read this Infographic highlighting the effectiveness of PEG-PG/HP-Guar as tear substitutes in improving ocular surface disease index and tear film breakup time in DED patients. Read More Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Paroxysmal Occipital Headache in Male

MedSynapse, Connecting doctors globally. Community of Doctors A 52-year-old male presented with a headache for 1 week. The headache was mainly located in the occipital area with paroxysmal onset. A nervous system physical examination showed that Kernig’s sign was suspiciously positive, while no other positive signs were observed. Blood tests showed elevated C-reactive protein (CRP, 37.1 mg/L). However, (MRI) of the brain did not show any abnormalities. Notably, thyroid-stimulating hormone receptor antibody (TRAb), thyroid peroxidase antibody (TPOAb), and thyroglobulin antibody (TGAb) were all negative. Further examination of thyroid color ultrasound showed bilateral diffuse hypoechoic areas. A subsequent thyroid examination was conducted, which revealed mild tenderness, specifically in the left thyroid. Dr. Navdeep Singh 🕐 2 Mins Read Suggest Diagnosis This email is intended for Dr. Renukaprasad A R Unsubscribe / Change your email preferences. © 2023 MedSynapse, USA, Singapore, India, Dubai

India: Doctor Killed in Kerala, Strike Across State, HC Calls out Systemic Failure, and More

Dear Dr. Renukaprasad A R, Top Stories of the Day: IMA calls for strike in Kerala to protest against violence USFDA Approves Drug for Fabry Disease Thailand: Over 40% of Working People are Overweight Treatment for Early Diagnosed Gestational Diabetes Mellitus Webinar: Resection of Carotid Body Tumor Healthcare headlines that matter, brought to you every day by Docplexus Health Minute! Watch News Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Expert Views on Tackling Secondary Hypertension

Dear Dr. Renukaprasad A R, Did you know that 17th May marks World Hypertension Day, a global initiative to raise awareness about hypertension? Over a billion individuals worldwide have hypertension, and the WHO considers it the top risk factor for cardiovascular disease. In observance of World Hypertension Day, Sun Pharma and Docplexus have organized a LIVE webinar on 20th May 2023 at 7:00 PM IST. Join our expert, Dr. Pinakin V Parekh, who will discuss the role of hypertension, its impact on health, and the management of the silent disease. Click to Know More Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Managing DED & its Subtypes with PG-HPG Artificial Tears

Dear Dr. Renukaprasad A R, Dry eye disease (DED) is a global health problem and the leading cause of optometry and ophthalmology clinic visits.      Approximately 30-70% of DED patients may suffer from symptoms of both aqueous-deficient dry eye (ADDE) and evaporative dry eye (EDE). Further, more than 80% of clinical cases fall into the EDE or ADDE+EDE types, while 10% are solely ADDE. Hence, eye care practitioners must choose proper artificial tears for better DED and its subtypes' management. Did you know that lipid-containing artificial tears with propylene glycol-hydroxypropyl guar (PG-HPG) are more effective and well-tolerated in various subtypes of DED? Read this Infographic to understand the efficacy and safety of phospholipid nanoemulsion-based PG-HPG lubricant eye drops in managing various subtypes of DED. Click to Read Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Evaluating Sotagliflozin in Patients with T2D and Stage 3 CKD

MedSynapse, Connecting doctors globally. Community of Doctors Attention doctors! A new study has determined the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, in adults with type 2 diabetes and stage 3 chronic kidney disease. Dr. Janhavi Pradhan 🕐 3 Mins Read Read Now This email is intended for Dr. Renukaprasad A R Unsubscribe / Change your email preferences. © 2023 MedSynapse, USA, Singapore, India, Dubai